Patienter, der fik MK524A, nicotinsyre (depotformulering) eller placebo, tog også statiner (29% atorvastatin [5- 80 mg], 54% simvastatin [10- 80 mg], 17% andre statiner [2, 5- 180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), hvoraf 9% også tog ezetimibe [10 mg].
Patients receiving Trevaclyn, nicotinic acid (prolonged-released formulation), or placebo were also taking statins (29% atorvastatin [5-80 mg], 54% simvastatin [10-80 mg], 17% other statins [2.5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), of which 9% were also taking ezetimibe [10 mg].